SCHEMBL25560540

SCHEMBL25560540

CC(C)(C)C(NC(=O)c1ccc2cc(F)ccc2c1OCc1ccc(S(F)(F)F)cc1)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 2/20 0.38
▸ CA2 P00918 1/20 0.36
▸ ADAMTS4 O75173 4/20 0.36
▸ FFAR4 Q5NUL3 1/20 0.35
▸ FCER2 P06734 1/20 0.34
▸ MMP13 P45452 2/20 0.34
▸ MMP2 P08253 1/20 0.34
▸ MMP14 P50281 1/20 0.34
▸ KEAP1 Q14145 1/20 0.33
▸ NFE2L2 Q16236 1/20 0.33
▸ GRM5 P41594 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ MAOB P27338 2/20 0.32
▸ MAOA P21397 1/20 0.32
▸ PYGL P06737 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ LRRK2 Q5S007 1/20 0.32
▸ CNR1 P21554 1/20 0.32
▸ CNR2 P34972 1/20 0.32
▸ MME P08473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25549545 1.00 CXCR2 (0.38) CXCR2CA2ADAMTS4FFAR4FCER2
SCHEMBL38662651 0.88 CXCR2 (0.50) CXCR2ADAMTS4FFAR4MMP13GRM5
SCHEMBL23460975 0.88 CXCR2 (0.50) CXCR2ADAMTS4FFAR4MMP13GRM5
SCHEMBL23460977 0.88 CXCR2 (0.50) CXCR2ADAMTS4FFAR4MMP13GRM5
SCHEMBL25549526 0.88 CXCR2 (0.49) CXCR2CA2ADAMTS4MMP13PYGL
SCHEMBL25560308 0.88 CXCR2 (0.49) CXCR2CA2ADAMTS4MMP13PYGL
SCHEMBL25548714 0.88 CXCR2 (0.38) CXCR2FFAR4FCER2GRM5MAOB
SCHEMBL25549762 0.88 CXCR2 (0.38) CXCR2FFAR4FCER2GRM5MAOB
SCHEMBL23461871 0.87 CXCR2 (0.39) CXCR2FFAR4GRM5MAOBMAOA
SCHEMBL23461870 0.87 CXCR2 (0.39) CXCR2FFAR4GRM5MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885CA2 2646/4885ADAMTS4 4215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback